Simoni G, Bignami P, Civalleri D, Cosimelli M, Craus W, Percivale P L, Repetto M
Minerva Med. 1986 Jan 14;77(1-2):41-6.
Forty-nine patients with liver tumors have been submitted to regional arterial chemotherapy by means of either totally implantable Infusaid 400 pumps (29 casse) or implantable ports (20 cases). The latter were subsequently perfused with external pumps. There was one single major operative complication and no operative deaths. Most patients underwent continuous FUDR infusion. Access related complications in the Pump and Port groups respectively included 1 and 0 malfunctions, 7 and 2 seromas, 2 and 0 pocket necroses, 8 and 10 thromboses, 2 and 4 catheter dislocations, 0 and 2 portal breakages. Treatment was stopped for access related complications in 5 and 5 patients respectively. In most of those cases, however, more than 6 cycles of chemotherapy have been performed. The Infusaid 400 pumps showed a 12-month duration of 58.4% with a 13 month median versus 17% and 9 month median of the Ports. The difference was not significant. The new implantable systems give better results in comparison with traditional regional methods; the performance of the Port systems appear very similar to the totally implantable pumps, with an obvious advantage, however, for the pumps as far as quality of life is concerned.
49例肝肿瘤患者接受了区域动脉化疗,其中29例使用完全植入式Infusaid 400泵,20例使用植入式端口。后者随后通过外部泵进行灌注。仅发生1例严重手术并发症,无手术死亡病例。大多数患者接受了持续氟尿苷输注。泵组和端口组与通路相关的并发症分别包括1例和0例故障、7例和2例血清肿、2例和0例囊袋坏死、8例和10例血栓形成、2例和4例导管移位、0例和2例门静脉破裂。分别有5例和5例患者因与通路相关的并发症而停止治疗。然而,在大多数这些病例中,已经进行了超过6个周期的化疗。Infusaid 400泵的持续时间为12个月的占58.4%,中位持续时间为13个月,而端口组分别为17%和9个月中位持续时间。差异无统计学意义。与传统区域方法相比,新型植入式系统效果更好;端口系统的性能似乎与完全植入式泵非常相似,但就生活质量而言,泵具有明显优势。